Physician profile
Stephen Paul Daniel
NPI 1922537190
$1,118.76
in general payments reported to CMS, 2019-2025
19 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2022: $151 · 2024: $15.24 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $225.01 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $153.25 | 2025 | |
| Janssen Pharmaceuticals, INC | $124.55 | 2022 | |
| Vanda Pharmaceuticals INC. | $123.59 | 2025 | Fanapt |
| Corcept Therapeutics | $92.56 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $60.01 | 2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $48.36 | 2025 | |
| Pfizer INC. | $42.09 | 2019-2025 | |
| Novo Nordisk INC | $37.13 | 2022-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $34.44 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $24.62 | 2019 | |
| Inspire Medical Systems, INC. | $24.33 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $21.89 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $21.22 | 2025 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $19.60 | 2025 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.91 | 2025 | Gvoke Hypopen |
| Verona Pharma, INC. | $17.51 | 2025 | Ohtuvayre |
| Amgen INC. | $15.91 | 2025 | Otezla, Repatha |
| Tactile Systems Technology INC | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.